Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review

Size: px
Start display at page:

Download "Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review"

Transcription

1 Technological Advances in Radiotherapy for the Treatment of Localized Prostate Cancer - A Systematic Review Jayatissa R.M.G.C.S.B. (B.Sc.) Department of Radiography/Radiotherapy, Faculty of Allied Health Sciences University of Peradeniya Sri Lanka, Sri Lanka. Abstract Prostate cancer is one of the most common cancers among males and is the second leading cause of cancer-related death in males. Objectives; The aim of this study is to find out the technological advances in the treatment of localized prostate cancer, to find out the side effects for each of the researched technological changes and to determine the outcomes of each change in technology. Methods and Materials A systematic review was undertaken to provide evidence relevant to the above objectives. Results; it has been recognized that the most widely used treatment modality as new Intensity modulated, the RapidArc has also being used in current, delivering the treatment using the cyber knife since 2008 (26). The side effects observed are different for each change in technology, some side effects are common to more than one treatment option such as urinary incontinence observed with cryotherapy, surgery, conventional, brachytherapy, and High Intensity Focused Ultrasound. Some are observed with a single treatment method such as urethral sloughing observed only with cryotherapy. The best five-year outcome was observed with Intensity Modulated Radiotherapy (100%) and worst five year outcome identified was with cryotherapy (36%) for low risk cancers. For intermediate risk cancers the best was with Brachytherapy (100%) and worst with conventional (26%). pg. 1

2 Conclusions The most advanced treatment in for localized prostate cancer is based with four dimensional treatment planning systems. Side effects were varying in each change in technology and there was no common side effect to all treatment method on the published data studied. From the published data IMRT appears to be a favorable treatment method for localized prostate cancers. However, establishing the optimal mode of therapy for prostate cancer remains controversial. pg. 2

3 Introduction Prostate cancer is one of the most common cancers among males and is the second leading cause of cancer-related death in males (46) In western societies and those who are emulating western lifestyles and diet there has been an increase in prostate cancer. In 2001 in the United States there were 31,900 reported deaths among the 198,100 new cases, where approximately one out of three persons is diagnosed with prostate cancer during their life time (13). In simple terms, prostate cancer can be divided into cancer that has not spread, which is called localized disease, and cancer that has spread, either "locally extending outside the prostate itself or involving distant organs, such as lymph nodes or bone ("distant" or metastatic disease). Localized prostate cancer is classified into risk groups as low risk, intermediate risk and the high risk group, for the purpose of deciding on a treatment method. The side effects and expected outcome of each treatment method will also depend on the external factors in deciding the best treatment modality for a localized prostate cancer. Standard treatments for localized prostate cancer include surgery, radiation therapy (external beam or brachytherapy with or without androgen ablation), or observation, which is also termed watchful waiting (46). The most adverse effect caused by irradiation of normal organs (38) in conventional methods are gastrointestinal, genitourinary, and sexual side effects. These effects should be reduced with the advances in technology. Several technical advances in have occurred over the last 20 years, conventional external beam (EBRT), three-dimensional (3DRT), intensity modulated (IMRT), image guided (IGRT), the cyber knife and the Rapid Arc techniques have all enhanced the precision of EBRT outcomes with minimal side effects. Methods and Materials A comprehensive review of the literature pertaining to technological advances in the treatment of localized prostate cancer was conducted using the Pubmed and Medline databases, and was supplemented with a data extraction from other key references/reviews, including the studies referred to in a recent literature articles. With the key terms there were 225 English language journal articles but all of them didn t fulfill the inclusion criteria of the research or provided relevant information to the research. There were only 75 journal articles found with informative data pertaining to the study among them. With the key terms there were 225 English language journal articles but all of them didn t fulfill the inclusion criteria pg. 3

4 of the research or provided relevant information to the research. There were only 75 journal articles found with informative data pertaining to the study among them. Results and Discussion 1. Technological advances in the treatment of localized prostate cancers 1.1. Brachytherapy There have been several changes added to the practice of Brachytherapy for prostate cancers over the last 100 years. In the first attempt radium needles were used and there was a period in the 1920s when radon seeds were also used (2). Currently it is possible to implant the radioactive materials such as iodine-125 or palladium-103 seeds permanently or high dose iridium-192 sources temporally through catheters (38) High Intensity Focused Ultrasound In 1942 HIFU (High Intensity Focused Ultrasound) had been introduced for treatment of cancers but its actual implementation for prostate cancers was in the early 1990s and in 1996 for benign prostatatic hypertrophy (40) Conventional Conventional has been used since the 1950s (9). New treatment machines such as linear accelerators, having more than 4MV energy, have replaced the Co-60 machines used throughout the past decades Cryotherapy In the 1960s liquid nitrogen in the form of ice packs was used for cryotherapy but in earlier times low temperatures had been used for this technique (46). Most recently the development of a temperature feedback automated freezing system have indicated its potential use in patients with localized prostate cancer (40) Three Dimensional Conformal Radiotherapy In the last past 5-10 years, major advances in planning and delivery of external beam occurred (33). In the mid 1980s 3D-CRT was first available, and now 3D-CRT has combined CT and MRI imaging with computerized planning to optimize prostate localization, delineation and dose distribution (5). pg. 4

5 1.6. Surgery According to the publication in 2003, the surgical perspective nerve sparing radical prostatectomy was the fundamental concept for localized prostate cancer treatment Rapidarc Since 2008 a form of new IMRT, the RapidArc is also been used in current, delivering the treatment using the cyber knife (26). It has the ability to deliver non coplanar non isocentric arcs to maximally conform isodoses. Fiducial markers are implanted in the prostate to verify the organ position and planning is provided by inverse planning Intensity Modulated Radiotherapy According to the published literature in 2006, the next generation came with the development of IMRT (18). In addition the imaging of implanted fiducial markers with computed tomography has been developed (18). The ability to image the daily prostate position has allowed the development of the IGRT technique Image Guided During the last decade, improvements in imaging with CT, MRI and PET scanning have allowed better localization of tumour volumes and more accurate treatment planning. Recent studies have demonstrated that treatment accuracy in delivery could be improved with the use of online imaging Proton therapy In 2010 a treatment method opposed to conventional photon therapy, in the form of particle therapy (proton therapy) is used to treat prostate cancers (33). This is a very new technique in the treatment of prostate cancers Stereotactic It is a new technique, so there is limited published data (33). 2. Side effects for each of the researched technological changes Gastrointestinal side effects Recto urethral fistula Longa J, P. in March 2001 had presented their research data on cryotherapy (24). pg. 5

6 Table 1. Prevalence of Recto urethral fistula References Treatment modality Study sample Results (24) cryotherapy % Acute proctitis According to the data and their sample the most valid data were produced by the U.S National Institute of Health, because their study sample size is large than the study in US by Perez, C A, 2000 (37). Table 2. Prevalence of Acute proctitis References Treatment modality Study sample Results (39) Surgery % Conventional % (37) Conventional 131 8% 3DCRT % Diarrhoea The most valid data (20.9%) being treat by the U.S. National institute of health compared to the other researchers because of their study sample (901 patients) is large. Table 3. Prevalence of Diarrhoea References Treatment modality Study sample Results (39) Conventional % Surgery % (37) 3DCRT % pg. 6

7 Bowel urgency The U.S. National Institute of Health published data (14.5%) on surgery proven to be more valid than the conventional data (35.7%) due to the large sample (901 patients) size in surgery. Table 4. Prevalence of Bowel urgency References Treatment modality Study sample Results (39) Surgery % conventional % Late grade 2 rectal toxicity The most valid data (2.9%) may be from Katz, A J, in 2010 due to the large sample size (206 patients) than the other treatment methods. Table 5. Prevalence of Late grade 2 rectal toxicity References Treatment modality Study sample Results (49) 3DCRT 61 14% (35) 116 8% (52) Brachytherapy % (49) IMRT 189 2% (35) IMRT 166 5% (19) Stereotactic % Rectal injury Rectal injury was only identified with Brchytherapy and it was published in UK by Ash, D, 2005 (2). Table 6. Prevalence of Rectal injury References Treatment modality Study sample Results (2) Brachytherapy % pg. 7

8 Acute grade 2 rectal toxicity In the published journal articles more valid statistics may have been produced by stereotactic by Schulte RW, in 2000, because of the large sample of patients been studied. Table 7. Prevalence of Acute grade 2 rectal toxicity References Treatment modality Study sample Results (5) IMRT % (51) % (19) Stereotactic % (41) Proton therapy % Acute GI toxicity Acute GI toxicity could be found only from IMRT and it was reported on a single journal article by Ghadjar, P in 2008 in Switzerland. Table 8. Prevalence of Acute GI toxicity References Treatment modality Study sample Results (12) IMRT 39 3% Late grade 2 GI toxicity The more valid data may have been produced with the IGRT treatments, the research had conducted by Martin,M,J, in 2009, because their study sample being larger than the other research study. pg. 8

9 Table 9. Prevalence of Late grade 2 GI toxicity References Treatment modality Study sample Results (12) IMRT 39 8% (28) IGRT % Grade 2 rectal bleeding By Zelefsky, M, J, in October 2006 observed Grade 2 rectal bleeding with the treatment of IMRT and they had resulted 1.6% of grade 2 rectal bleeding among 561 patients. Table 10. Prevalence of Grade 2 rectal bleeding (49) IMRT % Grade 3 rectal toxicity More accurate data was obtained by Zelefsky, M J, in August 2002, because they had taken a larger sample size than the other studies. Table 11. Prevalence of Grade 3 rectal toxicity (49) IMRT % (51) % (41) Proton therapy 870 0% Grade 2 late rectal bleeding The more valid data may have produced by Zelefsky, M, J, in 2002 because their sample size larger than the other study. pg. 9

10 Table 12. Prevalence of Grade 2 late rectal bleeding (51) IMRT % (35) 166 2% Late grade 3 GI toxicity and Late grade 2-3 GI toxicity According to the sample size the more valid data not obvious, due to the study sample size on both studies become equal. Table 13. Prevalence of Grade 3 late GI toxicity and Grade 2-3 late GI toxicity (28) IGRT % % 2.2. Genitourinary side effects Urethral sloughing Comparing the studies the study done in India may have more validity of data than the other studies because of their larger study sample size. Table 14. Prevalence of Urethral sloughing (40) Cryotherapy % (8) % (46) 37 10% Urinary incontinence The U.S. National institute of health had conducted studies with sample size of 1156 patients may have a higher validity. pg. 10

11 Table 15. Prevalence of Urinary incontinence (40) Cryotherapy % (8) % (46) 37 72% (24) % (39) Surgery % % %-16% (39) Conventional % 286 4% (27) Brachytherapy 271 4%-6% (40) HIFU % Testicular abscess Testicular abscess was only observed with cryotherapy in a study conducted by Donnellya, J, B Table 16. Prevalence of Testicular abscess (8) Cryotherapy % Impotence According to the one of the studies done with a total number of 1156 patients 80% of impotence was observed and the other study published 79.6% of patients as having affected for a total of 901 patients. The more valid prevalence of impotence may be from the former study which had 1156 patients. pg. 11

12 Table 17. Prevalence of Impotence (46) Cryotherapy 37 59% (24) % (39) Surgery % % (39) Conventional % % (2) Brachytherapy % Erectile dysfunction Among all the published journal articles the most valid data was provided by U.S. National institute of health (79.3%) compared to other studies due its larger population (901) than the others. Table 18. Prevalence of Erectile dysfunction (27) Surgery % (39) % % (39) Conventional % (52) 3DCRT 137 2% (27) Brachytherapy % (52) % (27) IMRT % (40) HIFU % Acute Grade 1 urinary symptoms The most valid data may have on the surgery because of the large study sample. pg. 12

13 Table 19. Prevalence of Acute grade 1 Urinary symptoms (27) Surgery 602 7% Brachytherapy % IMRT % Urinary strictures Among both treatment modalities, the most valid data was on surgery because of the sample size is larger than the study under conventional. Table 20. Prevalence of Urinary strictures (39) Surgery % Conventional % Dysuria These side effects were mentioned as separately observed side effects in the article. In this observation also had more accurate data for 3DCRT treatment results because of the large study sample size (146 patients). Table 21. Prevalence of moderate Dysuria (37) 3DCRT 146 5% Conventional 131 6% pg. 13

14 Table Prevalence of Dysuria (37) 3DCRT % Conventional 131 9% Moderate urinary frequency On this data most accurate information was provided for 3DCRT as its sample size (146 patients) is larger. Table 22. Prevalence of moderate urinary frequency (37) Conventional % 3DCRT % Nocturia Comparing both studies the most valid data provided by 3CDRT treatment side effect because of relatively large sample size to conventional study. Table 23. Prevalence of Nocturia (37) Conventional % 3DCRT 146 8%-19% Acute grade 2 urinary toxicity The most valid data (4%) was published by Katz, A J, in 2010 due to large sample size (304 patients) than the other studies. pg. 14

15 Table 24. Prevalence of Acute grade 2 urinary toxicity (49) 3DCRT 61 4%-13% (52) 137 8% (52) Brachytherapy % (19) Stereotactic 304 4% (19) Stereotactic % Late grade 2 urinary toxicity The most valid data may have been the one published by Zelefsky, M J, in August 2002 as their study sample size (772 patients) is larger than the other study. Table 25. Prevalence of Late grade 2 urinary toxicity (52) 3DCRT 137 2% (51) IMRT 772 9% Grade 3 urinary toxicity More valid data were published by the Zelefsky MJ, in August 2002 study compared to other researches. Table 26. Prevalence of Grade 3 urinary toxicity (52) 3DCRT 137 6% Brachytherapy % (49) IMRT 571 3% (51) % pg. 15

16 Urinary retention Comparing both studies more valid data may be produced by Zelefsky, MJ, in August 2002 in study as their sample size (772 patients) being larger than study on brachytherapy. Table 27. Prevalence of Urinary retention (23) Brachytheprapy 67 33% (51) IMRT % Urethral symptoms The urethral symptom identified only for a single article for Brachytherapy and it was published by UK research study (2). Table 28. Prevalence of Urethral symptoms (2) Brachytherapy % Grade 3 GU toxicity In a research conducted in Switzerland by Ghadjar, P in 2008 had observed grade 3 GU toxicity with IMRT. Table 29. Prevalence of Grade 3 GU toxicity (12) IMRT 39 3% Late grade 2 GU toxicity More accurate data was obtained by Martin, M, J, in 2009, because they had taken a larger sample size (222 patients) than the other study. pg. 16

17 Table 30. Prevalence of Late grade 2 GU toxicity (12) IMRT 37 15% (28) IGRT % Urethral toxicity/ strictures In USA Zelefsky, M, J, in October 2006 had conducted a study on IMRT and observed urethral toxicity/ strictures. Table 31. Prevalence of urethral toxicity/ strictures (49) IMRT % Acute grade 2 Urinary symptoms In USA Zelefsky, MJ, in August 2002 had conducted a study on IMRT. Table 32. Prevalence of Acute grade 2 Urinary symptoms (51) IMRT % Urinary tract infection Ranjan P, in 2008 conducted and observed Urinary tract infection for HIFU, 5% of the patients had this side effect in a study of 315 patients. Table 33. Prevalence of Urinary tract infection (40) HIFU 315 5% pg. 17

18 Bladder toxicity For proton therapy Schulte R, W, in 2000 conducted a research and they observed Bladder toxicity of 5.4% of patients among the study sample of 870 patients. Table 34. Prevalence of Bladder toxicity (41) Proton therapy % 2.3. Other side effects Perineal pain Perineal pain was only observed with cryotherapy in a study conducted by Theodorescu, Krupski, 2008, with a 37 patient sample 44% of affected patients. Table 35. Prevalence of Perineal pain (46) Cryotherapy 37 44% Cardiopulmonary complications The patient sample size of 1156 is evaluated with a large number of patients than the other, hence it is provided more valid data. Table 36. Prevalence of Cardiopulmonary complications (39) Surgery % Conventional % Implanted sources migrated to lungs There was only one research publication found related to seeds or implanted sources migrated to lungs that was observed on brachytherapy. pg. 18

19 Table 37. Prevalence of Implanted sources migrated to lungs (15) Brachytherapy %-15% 3. Outcomes for each change in technology Cryotherapy More valid data was published by Longa J, P. in 2001 compared to other studies because they had taken a large number of patients to study. The five year survival ranged from 36% to 92% for low risk disease and for intermediate patients it was in the range of 61% to 89% for cryotherapy treatments. Table 38. Five year outcomes of low risk and intermediate risk prostate cancer patients from Cryotherapy References Study sample Five year survival rate Low risk Intermediate risk (40) Not mentioned 60%-92% 61%-89% (8) 72 89% (3) 93 61%-92% (3) % (24) %-61% 3.2. Watchful waiting Under watchful waiting there was only one article publication found and the five year survival for low risk localized prostate cancer patients. Table 39. Five year outcomes of low risk and intermediate risk prostate cancer patients from Watchful waiting References Study sample Five year survival rate Low risk Intermediate risk (46) % pg. 19

20 3.3. Surgery The prevalence of five year survival for low risk range from 76% to 98% and for intermediate risk patients range from 37% to 77%. More accurate data may be published by the study conducted by Pisansky in 2006 due to the large patient sample in the study. Table 40. Five year outcomes of low risk and intermediate risk prostate cancer patients from Surgery References Study sample Five year survival rate Low risk Intermediate risk (40) Not mentioned 76%-98% 37%-77% (38) % (30) % (21) % 3.4. Conventional The survival data for low risk disease had ranged from 35% to 93% and for intermediate risk patients it ranged from 26% to 69.8%. According to the study of published articles more valid data may have been identified by Pisansky in 2006, because it had the larger sample size (2291 patients) than the other studies. pg. 20

21 Table 41. Five year outcomes of low risk and intermediate risk prostate cancer patients from Conventional Radiotherapy References Study sample Five year survival rate Low risk Intermediate risk (40) Not mentioned 81%-86% 26%-60% (38) %-81% (4) % (34) % 43%-62% (2) % 69.8% (30) % (21) %-81% (37) 94 65% 20 40% 3.5. Three Dimensional Conformal Radiotherapy The study data on five year survival ranged low risk patient from 85% to 96% and the intermediate risk patient survival ranged from 58% to 88% in the published articles. More valid data have been identified by Zelefsky et al, in Table 42. Five year outcomes of low risk and intermediate risk prostate cancer patients from Three Dimensional Conformal Radiotherapy References Study sample Five year survival rate Low risk Intermediate risk (49) % 58% (52) % (37) % 26 88% (35) % pg. 21

22 3.6. Brachytherapy According to the published data the survival data for low risk patients has ranged from 78% to 95% and for intermediate risk disease ranged from 60% to 100%. But among the published data the more valid data may be published by Pisansky in 2006 as there was a larger sample size than in the other studies. Table 43. Five year outcomes of low risk and intermediate risk prostate cancer patients from Brachytherapy References Study sample Five year survival rate Low risk Intermediate risk (40) Not mentioned 78%-89% 66%-82% (33) Not mentioned 95% 88%-100% (10) 33 79% 34 71% (38) % (2) Not mentioned 85%-90% 60%-70% (21) % (52) % 3.7. Intensity Modulated Radiotherapy In the published data the low risk survival prevalence range from 92% to 100% and intermediate risk patient survival has ranged from 85% to 96%. And according to the published data more valid data was published by Zelefsky, MJ, in August 2002 as they has taken a larger sample size than the other studies in the world. pg. 22

23 Table 44. Five year outcomes of low risk and intermediate risk prostate cancer patients from Intensity Modulated Radiotherapy References Study sample Five year survival rate Low risk Intermediate risk (32) % 85% (49) % 96% (51) % 86% (35) % 3.8. Image Guided Radiotherapy According to the publication more valid data were produced for intermediate risk patient statistics, because they had selected a large number of patients to study. Table 45. Five year outcomes of low risk and intermediate risk prostate cancer patients from Image Guided Radiotherapy References Study sample Five year survival rate Low risk Intermediate risk (28) % % 3.9. High Intensity Focused Ultrasound In the analyzed data the more valid statistics were published by Toyoaki, U, in 2006 as they had taken a larger sample size (181) to study than the other studies. These observed outcomes of five year survival range from 75% to 94% for low risk disease and 67% to 78% for intermediate risk patients. pg. 23

24 Table 46. Five year outcomes of low risk and intermediate risk prostate cancer patients from High Intensity Focused Ultrasound References Study sample Five year survival rate Low risk Intermediate risk (40) % 67% (40) % 78% (47) % 75% Proton therapy The observed statistics ranged from 82% to 90% for low risk disease patients. And according to the analysed statistics more valid data may have been produced by Slater J D, in 2004 on low risk localized prostate cancer patients due to their study sample size (1255) which was larger compared to other studies. Table 47. Five year outcomes of low risk and intermediate risk prostate cancer patients from Proton therapy References Study sample Five year survival rate Low risk Intermediate risk (42) % (43) % (41) % pg. 24

25 Conclusions The research results showed that the technological innovations were between 1920 and Side effects were varying for localized prostate cancer treatments in each change in technology and there was no common side effect to all treatment method on the published data studied. IMRT was associated with minimal percentile side effects. Proton therapy and HIFU has associated with the minimum number of side effects. From the published data IMRT appears to be a favorable treatment method for localized prostate cancers. According to analyzed data for low risk prostate cancer, the maximum five year survival was identified with IMRT hence it is the best treatment method for low risk diseased patients. The least percentage was observed with conventional, hence it is not a favorable treatment for localized prostate cancer patients. pg. 25

26 Acknowledgement I owe a great many thanks to a great many people who helped and supported me during the writing of this project report. My deepest thanks to Dr. P. Badra Hewavithana, former Head of the Department Radiography/Radiotherapy, and Mr. Joycelyn Cottrell, Therapy radiographer, Australia. I would like to thank all the members in Department of Radiography/Radiotherapy at the faculty of allied health sciences. Declaration I do hereby declare that the work reported in this project thesis was exclusively carried out by me under the supervision of Dr. P. Badra Hewavithana and Mr. Joycelyn Cottrell. It describes the results of my own independent research except where due reference has been made in the text. No part of this project thesis has been submitted earlier or concurrently for the same or any other degree. Accepted: 20 th September 2011 pg. 26

Prostate Cancer. What is prostate cancer?

Prostate Cancer. What is prostate cancer? Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum, below the bladder and above the base of the penis. Your doctor may perform

More information

Prostate Cancer. What is prostate cancer?

Prostate Cancer. What is prostate cancer? Scan for mobile link. Prostate Cancer Prostate cancer is a tumor of the prostate gland, which is located in front of the rectum and below the bladder. Your doctor may perform a physical exam, prostate-specific

More information

Prostate Cancer Treatment

Prostate Cancer Treatment Scan for mobile link. Prostate Cancer Treatment Prostate cancer overview Prostate cancer is the most common form of cancer in American men, most prevalent in men over age 65 and fairly common in men 50-64

More information

Chapter 18: Glossary

Chapter 18: Glossary Chapter 18: Glossary Sutter Health Cancer Service Line: Prostate Committee Advanced cancer: When the cancer has spread to other parts of the body (including lymph nodes, bones, or other organs) and is

More information

BRACHYTHERAPY FOR PROSTATE CANCER. Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital

BRACHYTHERAPY FOR PROSTATE CANCER. Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital BRACHYTHERAPY FOR PROSTATE CANCER Dr Brandon Nguyen MBBS(Hons), FRANZCR Radiation Oncologist, The Canberra Hospital PROSTATE BRACHYTHERAPY Why brachytherapy? How do we do it? What are the results? Questions?

More information

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).

What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,

More information

GYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology

GYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology GYNECOLOGIC CANCER and RADIATION THERAPY Jon Anders M.D. Radiation Oncology Brachytherapy Comes from the Greek brakhus meaning short Brachytherapy is treatment at short distance Intracavitary vs interstitial

More information

Prostate Cancer Treatments. Hasan Murshed, MD., DABR Radiation Oncology Residency, UAB Fellowship, MDACC Board Certified, ABR

Prostate Cancer Treatments. Hasan Murshed, MD., DABR Radiation Oncology Residency, UAB Fellowship, MDACC Board Certified, ABR Prostate Cancer Treatments Hasan Murshed, MD., DABR Radiation Oncology Residency, UAB Fellowship, MDACC Board Certified, ABR A Brief History of Radiation Wilhelm Roentgen discovered X- rays on November

More information

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical

More information

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49 OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection

More information

First, how does radiation work?

First, how does radiation work? Hello, I am Prajnan Das, Faculty Member in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center. We are going to talk today about some of the basic principles regarding

More information

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends

Prostate Cancer: Low Dose Rate (Seed) Brachytherapy. Information for patients, families and friends Prostate Cancer: Low Dose Rate (Seed) Brachytherapy Information for patients, families and friends About this booklet This booklet is designed to give you information about low dose-rate (seed) brachytherapy

More information

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008

Radiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008 Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators

More information

Patient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for

Patient Information. Prostate Tissue Ablation. High Intensity Focused Ultrasound for High Intensity Focused Ultrasound for Prostate Tissue Ablation Patient Information CAUTION: Federal law restricts this device to sell by or on the order of a physician CONTENT Introduction... 3 The prostate...

More information

ADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER

ADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER ADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER Bro. Dr. Collie Miller IARC/WHO Based on trends in the incidence of cancer, the International Agency for Research on Cancer (IARC) and WHO

More information

External Beam Radiotherapy for Prostate Cancer

External Beam Radiotherapy for Prostate Cancer External Beam Radiotherapy for Prostate Cancer Chomporn Sitathanee, Radiation Oncology Unit Ramathibodi Hospital, Mahidol University Roles of RT in prostate cancer Definitive RT; intact prostate Post radical

More information

Definition Prostate cancer

Definition Prostate cancer Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation

More information

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Radiotherapy

More information

Prostate cancer. Treatments Side effects and management in the community setting

Prostate cancer. Treatments Side effects and management in the community setting Prostate cancer Treatments Side effects and management in the community setting Kristoffer Ohlin CNS Urology Janice Minter Lead Cancer Nurse St George s Hospital Agenda Prostate cancer treatments Radiotherapy

More information

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Radiotherapy

More information

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of

More information

PROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College

PROSTATE CANCER BRACHYTHERAPY. Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College PROSTATE CANCER BRACHYTHERAPY Kazi S. Manir MD,DNB,PDCR RMO cum Clinical Tutor Department of Radiotherapy R. G. Kar Medical College Risk categorization Very Low Risk Low Risk Intermediate Risk High Risk

More information

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last

More information

An introduction to different types of radiotherapy

An introduction to different types of radiotherapy An introduction to different types of radiotherapy Radiotherapy can cure cancer. It is delivered to around half of cancer patients and is a vital part of curative treatment in around 40% of patients 1.

More information

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer

Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.

More information

When to worry, when to test?

When to worry, when to test? Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October

More information

Section: Therapy Effective Date: October 15, 2016 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:

Section: Therapy Effective Date: October 15, 2016 Subsection: Therapy Original Policy Date: December 7, 2011 Subject: Last Review Status/Date: September 2016 Page: 1 of 10 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate

More information

Radiotherapy physics & Equipments

Radiotherapy physics & Equipments Radiotherapy physics & Equipments RAD 481 Lecture s Title: An Overview of Radiation Therapy for Health Care Professionals Dr. Mohammed Emam Vision :IMC aspires to be a leader in applied medical sciences,

More information

TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY

TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 1 TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY BRENDAN CAREY, MD TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 2 TRANSRECTAL ULTRASOUND-GUIDED

More information

Your Guide to Prostate Cancer

Your Guide to Prostate Cancer Your Guide to Prostate Cancer If you face a diagnosis of prostate cancer, what s next? We can help. A prostate cancer diagnosis can be overwhelming. The good news is that while prostate cancer can be serious,

More information

Radiation Therapy. External Beam Radiation Therapy

Radiation Therapy. External Beam Radiation Therapy Radiation Therapy Radiation therapy is a non-invasive treatment for prostate cancer that uses x-rays or gamma-rays to eradicate prostate cancer cells. There are several forms of radiation therapy that

More information

New Technologies for the Radiotherapy of Prostate Cancer

New Technologies for the Radiotherapy of Prostate Cancer Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the

More information

Prostate Cancer. David Wilkinson MD Gulfshore Urology

Prostate Cancer. David Wilkinson MD Gulfshore Urology Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)

More information

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April

Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April Trina Lynd, M.S. Medical Physicist Lifefirst Imaging & Oncology Cullman, AL Tri-State Alabama, Louisiana and Mississippi Spring 2016 Meeting April 17, 2016 Discuss permanent prostate brachytherapy and

More information

High-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date

High-Dose Rate Temporary Prostate Brachytherapy. Original Policy Date MP 8.01.15 High-Dose Rate Temporary Prostate Brachytherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return

More information

20 Prostate Cancer Dan Ash

20 Prostate Cancer Dan Ash 20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised

More information

TOOKAD (padeliporfin) Patient Information Guide

TOOKAD (padeliporfin) Patient Information Guide TOOKAD (padeliporfin) Patient Information Guide TOOKAD is used to treat low-risk localized prostate cancer This medicine is subject to additional monitoring. This will allow quick identification of new

More information

The future of radiation therapy. Safe and innovative options, including the CyberKnife System

The future of radiation therapy. Safe and innovative options, including the CyberKnife System The future of radiation therapy Safe and innovative options, including the CyberKnife System Could a nonsurgical treatment be right for you? When you ve been diagnosed with a cancerous or noncancerous

More information

Radiotherapy to the prostate

Radiotherapy to the prostate Radiotherapy to the prostate Information for patients The aim of this leaflet is to provide you with information about the use of external beam radiotherapy in treating prostate cancer, including details

More information

Prostate Cancer Treatment Decision Information Background

Prostate Cancer Treatment Decision Information Background Prostate Cancer Treatment Decision Information Background A group of Radiotherapy Clinics of Georgia (RCOG) prostate cancer (PCa) patients developed this web site, in part, based on a slide presentation

More information

I. Equipments for external beam radiotherapy

I. Equipments for external beam radiotherapy I. Equipments for external beam radiotherapy 5 linear accelerators (LINACs): Varian TrueBeam 6, 10 & 18 MV photons, 6-18 MeV electrons, image-guided (IGRT) and intensity modulated radiotherapy (IMRT),

More information

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK

Salvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option

More information

Breast Cancer. What is breast cancer?

Breast Cancer. What is breast cancer? Scan for mobile link. Breast Cancer Breast cancer is a malignant tumor in or around breast tissue. It usually begins as a lump or calcium deposit that develops from abnormal cell growth. Most breast lumps

More information

Evaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy

Evaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy Evaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy Rungdham Takam Thesis submitted for the degree of Doctor of Philosophy in The School of Chemistry

More information

Professor of Medicine. Division of General Internal Medicine. Department of Medicine. University of California San Francisco

Professor of Medicine. Division of General Internal Medicine. Department of Medicine. University of California San Francisco TITLE: Proton Therapy for Prostate Cancer AUTHOR: Judith Walsh, MD, MPH Professor of Medicine Division of General Internal Medicine Department of Medicine University of California San Francisco PUBLISHER:

More information

Prostate Cancer Dashboard

Prostate Cancer Dashboard Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment

More information

PROSTATE CANCER CONTENT CREATED BY. Learn more at

PROSTATE CANCER CONTENT CREATED BY. Learn more at PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL

More information

The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology description

The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology description In response to an enquiry from the Scottish Radiotherapy Advisory Group Number 37 June 2011 The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer Health technology

More information

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Gleason score Gleason score 2-4: well differentiated (seldom reported now): Low risk

More information

Breast Cancer. What is breast cancer?

Breast Cancer. What is breast cancer? Scan for mobile link. Breast Cancer Breast cancer is a malignant tumor in or around breast tissue. It usually begins as a lump or calcium deposit that develops from abnormal cell growth. Most breast lumps

More information

Stereotactic Ablative Radiotherapy for Prostate Cancer

Stereotactic Ablative Radiotherapy for Prostate Cancer Stereotactic Ablative Radiotherapy for Prostate Cancer Laurie Cuttino, MD Associate Professor of Radiation Oncology VCU Massey Cancer Center Director of Radiation Oncology Sarah Cannon Cancer Center at

More information

Brachytherapy for Prostate Cancer

Brachytherapy for Prostate Cancer Brachytherapy for Prostate Cancer Who should be thinking about this and why... Juanita Crook Professor Radiation Oncology University of Toronto Princess Margaret Hospital Many options watchful waiting?

More information

THE UROLOGY GROUP

THE UROLOGY GROUP THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,

More information

Understanding Radiation Therapy. For Patients and the Public

Understanding Radiation Therapy. For Patients and the Public Understanding Radiation Therapy For Patients and the Public Introduction to Radiation Oncology Radiation has been an effective tool for treating cancer for more than 100 years. Radiation oncologists are

More information

Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed

Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity

More information

Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy. Risk Acceptability

Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy. Risk Acceptability Advances and Challenges in Radiation Protection of Patients Modern Radiotherapy Risk Acceptability Versailles, France December 2-4, 2009 Fred A. Mettler Jr. M.,D., M.P.H. New Mexico Federal Regional Medical

More information

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment

2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous

More information

PSA is rising: What to do? After curative intended radiotherapy: More local options?

PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung

More information

Intensity Modulated Radiotherapy (IMRT) of the Prostate

Intensity Modulated Radiotherapy (IMRT) of the Prostate Medical Policy Manual Medicine, Policy No. 137 Intensity Modulated Radiotherapy (IMRT) of the Prostate Next Review: August 2018 Last Review: November 2017 Effective: December 1, 2017 IMPORTANT REMINDER

More information

Has radiotherapy the potential being focal?

Has radiotherapy the potential being focal? Has radiotherapy the potential being focal? György Kovács & Alexander Schlaefer* Interdisciplinary Brachytherapy Unit and *Institute of Robotics and Cognitive Systems, University of Lübeck / 1 100% 90%

More information

Radiotherapy Advances

Radiotherapy Advances Radiotherapy Advances Not Radiotherapy Principles IMRT IGRT Image Fusion Planning Introduction IMRT = Intensity Modulated RadioTherapy Restriction: IMRT with photon beams IMRT: Highly conformal technique

More information

General information about prostate cancer

General information about prostate cancer Prostate Cancer General information about prostate cancer Key points Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate. Signs of prostate cancer include

More information

Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds. Original Policy Date

Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds. Original Policy Date MP 8.01.11 Brachytherapy for Clinically Localized Prostate Cancer Using Permanently Implanted Seeds Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Revised

More information

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer

Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Tan Chek Wee 15 06 2016 National University Cancer Institute, Singapore Clinical Care Education Research

More information

Stereotactic ablative body radiation for prostate cancer SABR

Stereotactic ablative body radiation for prostate cancer SABR Stereotactic ablative body radiation for prostate cancer SABR John Armstrong. Sinead Callinan. Luke Rock. Beacon Hospital, Dublin, Ireland Low- Intermediate Risk Prostate Comparing treatment choices IMRT

More information

DOSIMETRIC OPTIONS AND POSSIBILITIES OF PROSTATE LDR BRACHYTHERAPY WITH PERMANENT I-125 IMPLANTS

DOSIMETRIC OPTIONS AND POSSIBILITIES OF PROSTATE LDR BRACHYTHERAPY WITH PERMANENT I-125 IMPLANTS DOSIMETRIC OPTIONS AND POSSIBILITIES OF PROSTATE LDR BRACHYTHERAPY WITH PERMANENT I-125 IMPLANTS Andrius IVANAUSKAS*, Eduardas ALEKNAVIČIUS*, Arvydas BURNECKIS*, Albert MILLER *Institute of Oncology Vilnius

More information

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT Frequently-Asked Questions What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication of prostate cancer, is available to you if you want

More information

Proton beam therapy for prostate cancer. 1. What is the clinical effectiveness of proton beam therapy in the treatment of prostate cancer?

Proton beam therapy for prostate cancer. 1. What is the clinical effectiveness of proton beam therapy in the treatment of prostate cancer? QUESTION(S) TO BE ADDRESSED Proton beam therapy for prostate cancer 1. What is the clinical effectiveness of proton beam therapy in the treatment of prostate cancer? 2. What is the cost effectiveness of

More information

The state of prostate cancer management and therapies, courtesy of Sperling Prostate Center in Florida

The state of prostate cancer management and therapies, courtesy of Sperling Prostate Center in Florida The state of prostate cancer management and therapies, courtesy of Sperling Prostate Center in Florida 1 QUALITY OF LIFE WITH AN AGING PROSTATE: THE PROTOCOL Dan Sperling, MD, DABR Medical Director The

More information

Localized Prostate Cancer and Its Treatment- A Patient Guide

Localized Prostate Cancer and Its Treatment- A Patient Guide Your Health Matters Localized Prostate Cancer and Its Treatment- A Patient Guide Department of Urology UCSF Helen Diller Family Comprehensive Cancer Center University of California. San Francisco 550 16th

More information

Brain Tumor Treatment

Brain Tumor Treatment Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can

More information

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University

More information

Introduction to clinical Radiotherapy

Introduction to clinical Radiotherapy Introduction to clinical Radiotherapy Sarah Brothwood Radiotherapy Practice Educator Rosemere Cancer Centre Sarah.brothwood@lthtr.nhs.uk 01772 522694 Radiotherapy We have been able to see and document

More information

Men s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018

Men s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018 Men s Health Topics Jerome Baca, MS, PA-C Albuquerque Urology Associates January 6 th, 2018 1 ns 2 Prostate Cancer (pca) Most common type of cancer in men 45-75yo > 95% is adenocarcinoma: CA arising from

More information

Colorectal Cancer Treatment

Colorectal Cancer Treatment Scan for mobile link. Colorectal Cancer Treatment Colorectal cancer overview Colorectal cancer, also called large bowel cancer, is the term used to describe malignant tumors found in the colon and rectum.

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 146 Effective Health Care Program Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review Executive Summary Background Prostate cancer

More information

MEDICAL MANAGEMENT POLICY

MEDICAL MANAGEMENT POLICY PAGE: 1 of 8 This medical policy is not a guarantee of benefits or coverage, nor should it be deemed as medical advice. In the event of any conflict concerning benefit coverage, the employer/member summary

More information

Medical Dosimetry Graduate Certificate Program IU Graduate School & The Department of Radiation Oncology IU Simon Cancer Center

Medical Dosimetry Graduate Certificate Program IU Graduate School & The Department of Radiation Oncology IU Simon Cancer Center Medical Dosimetry Graduate Certificate Program IU Graduate School & The Department of Radiation Oncology IU Simon Cancer Center All students accepted into the Medical Dosimetry Graduate Certificate Program

More information

Prostate Cancer Questions?

Prostate Cancer Questions? Cancers other than prostate Physicians with the Florida Radiation Oncology Group are experts in providing state-of-the-art and compassionate care for all types of cancer, including lung cancer, breast

More information

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News

Navigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools

More information

Subject: Image-Guided Radiation Therapy

Subject: Image-Guided Radiation Therapy 04-77260-19 Original Effective Date: 02/15/10 Reviewed: 01/25/18 Revised: 01/01/19 Subject: Image-Guided Radiation Therapy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Systematic Review of Brachytherapy & Proton Beam Therapy for Low-Risk Prostate Cancer: Preliminary Findings

Systematic Review of Brachytherapy & Proton Beam Therapy for Low-Risk Prostate Cancer: Preliminary Findings Systematic Review of Brachytherapy & Proton Beam Therapy for Low-Risk Prostate Cancer: Preliminary Findings May 28, 2008 Dan Ollendorf, MPH, ARM Chief Review Officer Systematic Review Objectives To compare

More information

PROGRESS IN RADIATION ONCOLOGY. Fox Chase Cancer Center. Jean Holland RN MSN AOCN Department of Radiation Oncology April 2017

PROGRESS IN RADIATION ONCOLOGY. Fox Chase Cancer Center. Jean Holland RN MSN AOCN Department of Radiation Oncology April 2017 PROGRESS IN RADIATION ONCOLOGY Fox Chase Cancer Center Jean Holland RN MSN AOCN Department of Radiation Oncology April 2017 Radiation Therapy Therapeutic use of electromagnetic energy from a machine or

More information

Defining Target Volumes and Organs at Risk: a common language

Defining Target Volumes and Organs at Risk: a common language Defining Target Volumes and Organs at Risk: a common language Eduardo Rosenblatt Section Head Applied Radiation Biology and Radiotherapy (ARBR) Section Division of Human Health IAEA Objective: To introduce

More information

AllinaHealthSystems 1

AllinaHealthSystems 1 2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology

More information

Prostate Cancer: High Dose Rate Brachytherapy. Information for patients, families and friends

Prostate Cancer: High Dose Rate Brachytherapy. Information for patients, families and friends Prostate Cancer: High Dose Rate Brachytherapy Information for patients, families and friends About this booklet This booklet is designed to give you information about high doserate (or HDR) brachytherapy

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate

More information

Prostate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT)

Prostate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT) Prostate Cancer Appraisal Addendum: Stereotactic Body Radiation Therapy (SBRT) The Institute for Clinical and Economic Review (ICER) has published appraisals on multiple management options for clinically-localized,

More information

Name of Policy: High-Dose Rate Temporary Prostate Brachytherapy

Name of Policy: High-Dose Rate Temporary Prostate Brachytherapy Name of Policy: High-Dose Rate Temporary Prostate Brachytherapy Policy #: 024 Latest Review Date: June 2014 Category: Therapy Policy Grade: C Background/Definitions: As a general rule, benefits are payable

More information

Treating Prostate Cancer

Treating Prostate Cancer Treating Prostate Cancer A Guide for Men With Localized Prostate Cancer Most men have time to learn about all the options for treating their prostate cancer. You have time to talk with your family and

More information

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924

EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without

More information

Description. Section: Therapy Effective Date: October 15, 2015 Subsection: Therapy Original Policy Date: December 7, 2011 Subject:

Description. Section: Therapy Effective Date: October 15, 2015 Subsection: Therapy Original Policy Date: December 7, 2011 Subject: Last Review Status/Date: September 2015 Page: 1 of 14 Description High-dose rate (HDR) temporary prostate brachytherapy is a technique of delivering a high-intensity radiation source directly to the prostate

More information

Medical Policy. MP High-Dose Rate Temporary Prostate Brachytherapy

Medical Policy. MP High-Dose Rate Temporary Prostate Brachytherapy Medical Policy MP 8.01.33 BCBSA Ref. Policy: 8.01.33 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Therapy Related Policies 7.01.79 Cryoablation of Prostate Cancer 8.01.10 Charged-Particle

More information

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA

Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-

More information

RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS

RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS RADIOTHERAPY: TECHNOLOGIES AND GLOBAL MARKETS HLC176A February 2015 Neha Maliwal Project Analyst ISBN: 1-62296-043-2 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

The Wellness Community Prostate Cancer

The Wellness Community Prostate Cancer The Wellness Community Prostate Cancer Large Discussion Group July 28, 2010 Kevin Chaffee Knowledge Navigator Tonight s Agenda Review peer reviewed informagon on proton therapy for prostate cancer treatment

More information

Palliative RT in Ovarian cancer

Palliative RT in Ovarian cancer Outline Palliative RT in Ovarian cancer Case discussion Palliative treatment Radiation Techniques Asst Prof Pittaya Dankulchai, MD. Division of Radiation Oncology, Department of Radiology, Faculty of Medicine

More information

New Radiation Treatment Modalities in the Treatment of Lung Cancer

New Radiation Treatment Modalities in the Treatment of Lung Cancer New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions

More information

Brachytherapy in prostate cancer: techniques and clinical outcomes

Brachytherapy in prostate cancer: techniques and clinical outcomes 19 Brachytherapy in prostate cancer: techniques and clinical outcomes MARK PRENTICE, WENLONG NEI, AMY LEWIS, REENA DAVDA AND HEATHER PAYNE Brachytherapy for prostate cancer involves placing radioactive

More information